Fulranumab

Drug Profile

Fulranumab

Alternative Names: AMG-403; JNJ-42160443

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Janssen Pharmaceuticals; Janssen Research & Development; Takeda
  • Class Monoclonal antibodies; Non-opioid analgesics; Peptides
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain
  • Discontinued Back pain; Cancer pain; Musculoskeletal pain; Neuropathic pain

Most Recent Events

  • 24 Jun 2016 Takeda terminates its licence for fulranumab in Japan
  • 31 Mar 2016 Discontinued - Phase-II for Back pain in Belgium, Canada and USA (SC)
  • 31 Mar 2016 Discontinued - Phase-II for Cancer pain (Adjunctive treatment) in USA, Spain, Portugal, Poland and France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top